Curative resection of carcinoma of the ampulla of Vater with lymph node metastases around the abdominal aorta after chemotherapy: A case report  by Fujii, Wataru et al.
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INTRODUCTION:  For  carcinoma  of  the ampulla  of  Vater,  lymph  node  metastasis  around  the  abdominal
aorta  is an  inoperable  factor  equivalent  to distant  metastasis,  such as  hepatic  metastasis  or  peritoneal
carcinomatosis,  making  the  cancer  unresectable.
PRESENTATION  OF  CASE:  A  53-year-old  man  was referred  to  our  hospital  and  was  diagnosed  as  having
carcinoma  of the  ampulla  of Vater  with  lymph  node  metastases  around  the  abdominal  aorta.  Although
only  chemotherapy  was  initially  scheduled,  the  chemotherapy  was  effective,  and  the  metastases  wereeywords:
urative resection
mpulla vater
hemotherapy
dramatically  reduced  after  4  cycles  of  chemotherapy.  Curative  surgical  resection  was  performed.
DISCUSSION:  There  were  only  eight  case reports  describing  curative  resections  of  initially  unresectable
biliary  tract  carcinomas  excluding  intrahepatic  cholangiocellular  carcinoma  after  chemotherapy.
CONCLUSION:  Curative  surgical  resection  after  chemotherapy  may  be a  feasible  treatment  plan  in patients
with  unresectable  biliary  tract  cancer.
 Publi
he CCase report
© 2016  The  Author(s).
access  article  under  t
. Introduction
For carcinoma of the ampulla of Vater, lymph node metastasis
round the abdominal aorta is an inoperable factor equivalent to
istant metastasis, such as hepatic metastasis or peritoneal carci-
omatosis, making the cancer unresectable [1]. Here, we report a
ase of carcinoma of the ampulla of Vater with lymph node metas-
ases around the abdominal aorta. The patient was able to undergo
 curative operation after completing chemotherapy with gemc-
tabine and cisplatin and has not shown any signs of recurrence for
6 months.
. Case report
A 53-year-old man  complaining of itching and yellow skin
isited a local hospital. He was suspected of having obstructive
aundice and was referred and admitted to our hospital for a thor-
ugh examination.
Upon examination, the abdomen was soft and ﬂat, with no
ass, tenderness, or rebound. Laboratory data at the time of admis-ion showed serum total bilirubin and direct bilirubin levels of
7.7 mg/dL and 13.0 mg/dL, respectively. The aspartate amino-
ransferase level was 122 IU/L, the alanine aminotransferase level
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was 205 IU/L, the alkali phosphatase level was  1647 IU/L, the
-glutamyl transpeptidase level was  1146 IU/L, and the lactate
dehydrogenase level was  270 IU/L. The carcinoembryonic antigen
(CEA) and DU-PAN-II levels were 7.5 ng/dL and 687 U/dL, but the
carcinoma 19-9 level was not elevated. The other test results were
normal. A computed tomography (CT) scan revealed a dappled
enhanced tumor 30 mm in size in the ampulla of Vater (Fig. 1a) with
invasion to the duodenum and pancreas. Regional lymph nodes
along the common hepatic artery (#8a) and in the hepatoduo-
denal ligament (#12b) had swollen to 21 mm  and 33 mm in size,
respectively (Fig. 1b, c); moreover, several distant lymph nodes
around the abdominal aorta were also swollen, with one located
between the upper border of the celiac artery and the lower border
of the left renal vein (#16a2) swollen to 21 mm  (Fig. 2a) and oth-
ers located between the lower border of the left renal vein and the
upper border of the origin of the inferior mesenteric artery (#16b1)
swollen to 19 mm and 20 mm  (Fig. 2b, c). An upper gastrointestinal
endoscopy showed an exposed protruded tumor in the ampulla of
Vater (Fig. 3a). Endoscopic retrograde cholangiopancreatography
(ERCP) showed bile duct dilatation, and an endoscopic retrograde
biliary drainage (ERBD) tube was  placed to alleviate the obstructive
jaundice (Fig. 3b). A pathological examination of the tumor revealed
a poorly differentiated adenocarcinoma.The clinical diagnosis at the time was  carcinoma of the ampulla
of Vater, exposed protruded type, T3b (Du2, Panc2), N1, H0, P0,
M1  (LYN), c-Stage IV in the classiﬁcation of biliary tract cancers
established by the Japanese Society of Hepato-Biliary-Pancreatic
Group Ltd. This is an open access article under the CC BY-NC-ND license (http://
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Fig. 1. CT scans show reduction of tumor (arrow heads) in the ampulla Vater (a,d), lymphnodes #8a (arrows) (b,e) and #12b (thick arrows) (c,f).
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urgery: 3rd English edition [1]. Because of lymph node metastases
round the abdominal aorta, chemotherapy with gemcitabine and
isplatin was performed at dosages of 1000 mg/m2 and 25 mg/m2
eekly for 2 weeks, followed by a week rest. Four cycles later, the
ancer markers CEA and DU-PAN-2 had decreased and were within
he normal ranges (Fig. 4). A follow-up CT scan showed the shrink-
ge of the tumor in the ampulla of Vater (Fig. 1d), the disappearance
f the lymph nodes at #8a (Fig. 1e), and the shrinkage of the lymph
odes at #12b (Fig. 1f) to 11 mm and 20 mm,  respectively. More-
ver, the lymph node at #16a2 (Fig. 2d) had shrunk to 7 mm and the
ymph nodes at #16b1 (Fig. 2e, f) had shrunk to 5 mm and 7 mm. (arrow heads) (a,d) and #16b1 (arrows) (b,c,e,f).
Consequently, the chemotherapy with gemcitabine and cisplatin
was judged to have induced a partial anticancer response. Because
of the acceptable chemotherapy response, surgical resection was
performed after obtaining informed consent. The operation con-
sisted of a subtotal stomach-preserving pancreaticoduodenectomy
with lymph node dissection of the regional lymph nodes and distant
lymph nodes around the abdominal aorta as well as a IIA-3 recon-
struction. The operation time was 578 min, and the blood loss was
2830 mL.
The tumor in the ampulla of Vater was  an exposed, protruded-
type mass, and the tumor specimen had decreased to a diameter of
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Fig. 3. ERCP revealed exposed protruded mass in the ampulla of Vater (a), and obstruction in bile duct (b).
Fig. 4. Clinical course and changes in DUPAN-II and CEA.
Fig. 5. A macrophotograph of tumor (a) in the ampulla Vater, and microphotographs of HE staining of tumor (×20) (b) and lymph node around the aorta (×1.25) (c).
Fig. 6. pathological ﬁndings of lymph node in the hepatoduodenal ligament, showing the results of HE staining (×1.25) (a) and immunostaing with CK AE1/3(×1.25) (b).
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Table  1
Cases of R0 resection of biliary tract carcinoma.
author location year age Inoperable reason chemo effect Stage f/u(mo) recurrence
Shirabe GB 2008 75 Lymph node metastasis
around the abd. Ao
GEM/CDDP/5FU improvement IV 25 none
Kitajima GB 2008 53 Peritoneal
dissemination
S-1 disappearance I – –
Morimoto GB 2008 69 Liver metastasis Lymph
node metastasis
around the abd. Ao
GEM disappearance IV 20 none
Hasegawa GB 2010 64 Lymph node metastasis
around the abd. Ao
S-1 disappearance IV 13 none
Takita GB 2011 57 Lymph node metastasis
around the abd. Ao
GEM/S-1 disappearance II 12 none
Rama GB 2013 74 Lymph node metastasis
around the abd. Ao
GEM/CDDP disappearance IV 16 None
Tanemura BD 2008 78 Liver metastasis GEM/rad disappearance – –
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5 mm (Fig. 5a). A pathological examination of the specimen using
ematoxylin and eosin (HE) staining showed necrotic tissue and
pithelia with dysplasia that was thought to be a remnant of adeno-
arcinoma (Fig. 5b). The invasion of inﬂammatory cells and ﬁbrosis
ith follicular histiocytes under the mucosa were observed near
he ampulla of Vater. The presence of histiocytes and ﬁbrosis in
he resected lymph nodes suggested inﬂammation (Fig. 5c). Espe-
ially, the immunostaining of lymph node #12b was  positive for
ytokeratin (CK) AE1/3 and was strongly suspected to have been a
etastasis originating from the ampulla of Vater carcinoma (Fig. 6a,
). However, the immunostaining of lymph nodes from around the
bdominal aorta was not positive for this factor, and only follic-
lar histiocytes and ﬁbrosis were observed, suggesting that these
car tissues might have been metastases originating from the carci-
oma. The pathological diagnosis was carcinoma of the ampulla of
ater, exposed protruded type, pT1(Du0, Panc0) ly0, v0, ne0, pN0,
HM0, pPM0, pEM0, pPV0, pA0, R0, p-Stage I. [1]
The patient was discharged on the 41st postoperative day
fter recovering from a pancreatic ﬁstula (grade II). Adjuvant
hemotherapy was not performed, and no evidence of recurrence
r metastases has been seen for 36 months since the operation.
. Discussion
According to in the Biliary Tract Cancer Statistics Registry in
apan, the 5-year survival rates after surgical resection are about
0% for whole biliary tract cancer, 33.1% for bile duct cancer, 41.6%
or gallbladder cancer, and 52.8% for ampulla of Vater cancer, while
hose of unresectable disease are 1% for bile duct cancer, 2% for
allbladder cancer, and 8% for ampulla of Vater cancer [2]. Ampulla
f Vater cancer accounts for 14.0% of biliary tract cancers and has
 high resectability rate of 89.4% and a curative resection rate of
3.0% [2]. For these reasons, ampulla of Vater cancer has a rel-
tively better prognosis, and surgery tends to be more effective,
ompared with similar surgical procedures for other biliary tract
ancers. However, invasion of the pancreas and (peri)neuroplexus
nd metastasis to lymph nodes worsens the prognosis consid-
rably, even for ampulla of Vater carcinoma [3,4]. Generally, in
atients with biliary tract cancer, long-term survival depends crit-
cally on complete tumor resection, and patients with distant
etastasis to the liver, lungs, bone, or peritoneum are not eligible
or surgery and instead are candidates for palliative chemother-
py [5–7]. Also, regional lymphadenectomy and lymphadenectomy
ear the abdominal aorta does not provide a survival beneﬁt to
atients with abdominal aortic disease, which has an inﬂuence
n the prognosis equivalent to that of distant metastasis [5,7].
hemotherapy with gemcitabine and cisplatin is the current stan-EM/S-1 disappearance III 14 None
EM/CDDP disappearance IV 36 None
dard for unresectable biliary tract cancer based on the results of the
ABC-02 trial, but this combination results in an antitumor activity
with an objective response rate of only 26.1% and a median survival
of 11.7 months [5,8,9].
We  searched the PubMed MEDLINE interface and the database of
the Japan Medical Abstracts Society for reports published between
1983 and 2014. The search strategy was designed to be inclu-
sive using the intersection of the following medical subject and
keyword headings: biliary tract carcinoma,  carcinoma of ampulla,
cholangiocellular carcinoma,  chemotherapy,  and resection. Accord-
ingly, we found eight case reports describing curative resections
of initially unresectable biliary tract carcinomas excluding intra-
hepatic cholangiocellular carcinoma after chemotherapy, and all of
these cases had favorable outcomes [10–17]. Six reports described
gallbladder cancers and one report each described bile duct can-
cer and ampulla of Vater cancer. Of these nine reports included our
case, many of them used different chemotherapy regimens. Two
reports used a combination of gemcitabine and S-1, two used a
combination of gemcitabine and cisplatin, and two  used S-1 alone.
One report used gemcitabine alone, one used gemcitabine and radi-
ation, and one used gemcitabine, cisplatin and 5-FU. Inoperable
factors were described as not only liver and lymph node metastases
around the abdominal aorta, but also peritoneal dissemination
(Table 1).
To our knowledge, only Oono et al. [10] has reported the curative
resection of an ampulla of Vater carcinoma after chemotherapy.
In their report, a 53-year-old patient had an ampulla of Vater
carcinoma with liver metastasis and underwent surgery after com-
pleting 3 cycles of chemotherapy with gemcitabine and S-1. Liver
resection was not performed because no evidence of liver metas-
tasis was seen during an intraoperative echography.
Some clinical problems exist for cases with initially unresectable
biliary tract cancer that becomes resectable after chemotherapy
because of the lack of evidence supporting this strategy. First, the
timing of such surgery remains uncertain. Some authors decided
to perform surgery once a complete or partial anticancer response
had been achieved, and one case report described the progression
of a liver metastasis despite continuous chemotherapy. Second, the
need for adjuvant chemotherapy also remains uncertain. Murakami
et al. [18] reported that adjuvant chemotherapy with gemcitabine
and S-1 may  be a promising strategy for patients with advanced
biliary tract cancer after curative resection. A randomized phase III
study is expected to show that adjuvant chemotherapy is effective
and well tolerated.
However, comparative studies are difﬁcult to conduct, since
few cases with conversions in treatment strategy exist. The further
accumulation of reports is awaited to conﬁrm the optimal timing
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. Conclusion
We  performed the curative resection of an ampulla of Vater can-
er in a patient with lymph node metastases around the aorta after
he completion of 4 cycles of gemcitabine and cisplatin chemother-
py. Curative surgical resection after chemotherapy may  be a
easible treatment plan in patients with unresectable biliary tract
ancer.
onﬂict of interest
None.
unding
No sources of funding.
thical approval
Kameda medical center ethics committee 16-039.
onsent
Written informed consent was obtained from the patient for
ublication of this case report and accompanying images.
uthor’s contributions
As 1st author, Wataru Fujii contributes to case report writ-
ng, data collection and discussion writing. All authors read and
pproved the ﬁnal manuscript.
egistration of research studies
This paper is not a research study.uarantor
Wataru Fujii.
[
[
pen Access
his article is published Open Access at sciencedirect.com. It is distrib
ermits unrestricted non commercial use, distribution, and reproduct
redited.PEN  ACCESS
ery Case Reports 28 (2016) 274–278
References
[1] Masaru Miyazawa, Masayuki Ohtsuka, Shuichi Miyazawa, et al., Classiﬁcation
of biliary tract cancers established by the Japanease Society of
Hepato-Biliary-Pancreatic Surgery: 3rd english edition, J. Hepatobiliary
Pancreat. Sci. 22 (2015) 181–196.
[2] Shuichi Miyakawa, Shin Ishihara, Akihiko Horiguchi, et al., Biliary tract cancer
treatment: 5584 results from the Biliary Tract Statistics Registry from 1998 to
2004 in Japan, J. Hepatobiliary. Pancreat. Surg. 16 (2009) 1–7.
[3] Shin Ishihara, Shuichi Miyagawa, Akihiko Horiguchi, et al., Recent trends of
ampullary cancer: results from biliary tract cancer statistics registry, J. Biliary
Tract Pancreas 33 (2012) 221–224.
[4] Hiroto Ishikawa, Hisafumi Kinoshita, Masanori Akashi, et al., Long-term
results and prognostic factors of pancreaticoduodenectomy for carcinoma of
the ampulla of vater, J. Biliary Tract Pancreas 33 (2012) 267–270.
[5] M.  Miyazaki, H. Yoshitomo, S. Miyazawa, et al., Clinical practice guidelines for
the  management of biliary tract cancers 2015: the 2nd English edition, J.
Hepatobiliary Pancreat. Sci. 22 (2015) 249–273.
[6] W.R. Jarnagin, Y. Fong, R.P. DeMatteo, et al., Staging, respectability, and
outcome in 225 patients with hilar cholangiocarcinoma, Ann. Surg. 234
(2001) 507–517.
[7] S. Kondo, Y. Mimura, N. Hayakawa, et al., Regional and para-aortic
lymphadenectomy in radical surgery for advanced gallbladder carcinoma, Br.
J.  Surg. 87 (2000) (418-122).
[8] M.D. Juan Valle, M.D. Harpreet Wasan, H.M.D. Daniel, et al., Cisplatin plus
gemcitabine versus gemcitabine for biliary tract cancer, N. Engl. J. Med. 362
(2010) 1273–1281.
[9] T. Okusaka, K. Nakachi, A. Fukutomi, et al., Gemcitabine alone or in
combination with cisplatin in patients with biliary tract cancer: a
comparative multicentre study in Japan, Br. J. Cancer 103 (2010) 469–474.
10] Tomoyoshi Ohno, Hiroki Koguchi, Aki Miura, et al., A case of advanced
ampullary carcinoma successfully resected after primary chemotherapy eith
S-1  and gemcitabine, Jpn. Cancer Chemother. 36 (6) (2009) 999–1002.
11] Haruki Morimoto, Tetsuo Ajiki, Shiro Takase, et al., Resection of gallbladder
cancer with hepatic metastasis after chemotherapy with gemcitabine, J.
Hepatobiliary. Pancreat. Surg. 15 (2008) 655–658.
12] Kumiko Kitajima, Susumu Kobayashi, Hiroaki Shiba, et al., Successful
Treatment of advanced gallbladder cancer with an anticancer drug S-1:
assessment based on intratumoral gene, Int. J. Clin. Oncol. 13 (2008) 545–551.
13] Rama Adikrisna, Noriaki Nakamura, Takumi Irie, et al., Curative resection of
stage IV advanced gallbladder cancer following combined treatment with
gemcitabine and CDDP, Jpn. Cancer Chemother. 41 (1) (2014) 117–120.
14] T. Ajiki, T. Okazaki, S. Murakami, et al., Surgical resection after effective
chemotherapy for initially unresectable biliary tract cancer, Jpn. J. Cancer Clin.
58  (5) (2012) 273–279.
15] Naoyuki Hasegawa, Masato Abei, Ryoko Sasaki, et al., A case with Stage IVb
advanced gallbladder cancer curatively resected following effective S-1
chemotherapy, JJBA 24 (2010) 723–728.
16] Ken Shirabe, Tomoyuki Abe, Kiyoshi Kajiyama, et al., The survival of
chemotherapy in the patients with gall bladder cancer – a pilot study, JJBA 22
(2008) 41–46.
17] Akihiro Uemura, Hiromichi Goshima, Hiroyuki Kato, et al., A resected case of
upper to middle bile duct cancer effectively treated with prospective
chemoradiation therapy, Biliary Tract Pancreas 29 (3) (2008) 263–269.
18] Yoshiaki Murakami, Kenichiro Uemura, Kakeshi Sudo, et al., Adjuvant
chemotherapy with gemcitabine and S-1 after surgical resection for advanced
biliary carcinoma: outcomes and prognostic factors, J. Hepatobiliary Pancreat.
Sci.  19 (2012) 306–313.uted under the IJSCR Supplemental terms and conditions, which
ion in any medium, provided the original authors and source are
